ClinicalTrials.gg
RecruitingNCT03206814CHARGE-APPUpdated Feb 27, 2025

Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System

An interventional study of Usual care and POST-strategy in Hypertension,Essential and Hypertension, Uncontrolled, sponsored by Istituto Auxologico Italiano. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.

Read the detailed description

CHARGE-APP is a proof-of-concept one-year prospective, randomized, open-label, blinded endpoint study (PROBE) including 2 groups of patients randomized to different treatment strategies:

  1. a new management strategy, named POST (i.e. "Patient Optimal Strategy for Treatment"), consisting in providing the patients with a system to communicate home blood pressure measurements to a referral centre, and the referral centre with an online platform to organize and easily interpret the information sent by patients and to monitor the patients' status;
  2. usual care, consisting in regular visits at the referral centre.

Patients will be enrolled over 3 months and will be randomly allocated to one of the study groups. Follow-up phase will last 12 months after randomization and will focus on changes in ambulatory systolic BP (primary endpoint), in diastolic ambulatory BP, in office SBP and DBP, in Home SBP and DBP, in left ventricular mass index (LVMI) and urinary albumin excretion (UAE), all secondary end-points.

All patients will perform visits at baseline, three, six and twelve months. Physical examination, history of the patient and clinical blood pressure values will be obtained at every visit.

Echocardiogram, ECG, urine samples (UAE, urinary albumin/creatinine and 24-h ambulatory blood pressure monitoring (ABPM) will be performed at baseline, three months, six months and study end.

Blood samples (full blood count, creatinine, Na+, K+, fasting glucose, HbA1c, uric acid, lipids) will be performed at baseline; another blood sample will be collected at twelve months for measurement of serum creatinine (and renal function). UAE will be measured at baseline and study end, on morning urine samples.

Patients randomized to POST-strategy will measure Home BP two days a week (two measurements in the morning and two measurements in the evening) and communicate these values with the ESH CARE app; furthermore, before each visit they will measure their Home BP for 7 consecutive days (two measurements in the morning and two measurements in the evening), according to current guidelines on hypertension.

Patients randomized to usual care will also measure Home BP for 7 consecutive days at baseline and at study end, to provide a comparison. Operators (i.e. investigators dedicated to the follow-up of POST-strategy) will check these data organized by the POST system at least every 15 days, and adjust pharmacological therapy, if needed.

In patients randomized to usual care, therapy will be adjusted only at follow-up visits (i.e. at three and six months).

Pharmacological therapy will be increased or decreased according to blood pressure values; investigators may follow a therapy algorithm based on ESH/ESC guidelines, but are free to individualize it.

02

Conditions studied

  • Hypertension,Essential
  • Hypertension, Uncontrolled

Keywords

  • Hypertension
  • Ambulatory Systolic Blood Pressure
  • Home Blood Pressure
  • ESH-CARE APP
03

In context

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

This study's planned enrollment of 480 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects;
  • Age 18-80 years;
  • Either the patient or another person close to him/her should possess a smartphone compatible with the ESH CARE app and be capable of using it;
  • Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140/90 mmHg, and Ambulatory 24h ABP ≥130/80 mmHg

Exclusion criteria

Exclusion Criteria:

  • \<45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009);
  • Severe uncontrolled hypertension (i.e. BP ≥200/120 mmHg despite treatment);
  • Known secondary hypertension;
  • Orthostatic hypotension (SBP fall > 20 mmHg on standing);
  • Unstable clinical conditions or severe disease with short life expectation;
  • Known atrial fibrillation;
  • Hepatic disease as determined by either or ALT values > 2 times the ;
  • History of gastrointestinal surgery or disorders which could interfere with drug absorption
  • History of including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years;
  • History of disorders such as systemic lupus erythematosus;
  • History of drug or alcohol abuse within the last 5 years;
  • History of non-compliance to medical regimens and/or patients who are considered potentially unreliable;
  • Dementia (clinical diagnosis);
  • Inability or unwillingness to give free ;
  • Inability to use even simple communication technologies;
  • Pregnancy or planned pregnancy during study period
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Active comparator
    Group 1 - Usual care

    Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.

    Other: Usual care

  • Experimental
    Group 2 - POST-strategy

    Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.

    Other: POST-strategy

Interventions

  • OtherUsual care

    Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.

  • OtherPOST-strategy

    Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.

06

What researchers measure

Primary outcomes

  1. Ambulatory Systolic Blood Pressure

    Change in ambulatory 24h systolic blood pressure

    Time frame: 12 months

Secondary outcomes

  1. Ambulatory Diastolic Blood Pressure

    Change in ambulatory 24h diastolic blood pressure

    Time frame: 12 months

  2. Difference between Office Blood Pressure and Home Blood Pressure

    Differences between office blood pressure and home blood pressure (both systolic and diastolic)

    Time frame: 12 months

  3. Left ventricular mass index

    Change in left ventricular mass index by ecocradiographic evaluation

    Time frame: 12 months

  4. Left ventricular hypertrophy

    Change in ECG indices of left ventricular hypertrophy

    Time frame: 12 months

  5. Urinary albumin to creatinine ratio

    Change in urinary albumin to creatinine ratio

    Time frame: 12 months

  6. Estimated glomerular filtration rate

    Change in estimated glomerular filtration rate

    Time frame: 12 months

  7. Normalization rate of blood pressure

    Normalization rate of BP by all the measuring devices: office BP, HOME BP and ABPM

    Time frame: 12 months

  8. ABPM variables

    Change in a number of variables derived from ABPM (day-time SBP/DBP, Night-time SBP/DBP, nocturnal dipping of SBP/DBP, morning surge of SBP/DBP, BPV (daytime and night-time SBP/SBP SD, CV; 24h SBP/DBP ARV, 24h SBP/DBP wSD, AASI)

    Time frame: 12 months

  9. Prescribed antihypertensive drugs

    Number of prescribed antihypertensive drugs

    Time frame: 12 months

07

Study locations

7 of 8 sites recruiting
  • Private Hospital " Dr Raúl Matera"
    Bahia Blanca, B8000, Argentina
    Recruiting
  • Argerich Hospital
    Buenos Aires, C155 AHD, Argentina
    Recruiting
  • General San Martin Hospital of La Plata
    La Plata, 1900, Argentina
    Recruiting
  • Spanish Hospital of Mendoza
    Mendoza, M5501, Argentina
    Recruiting
  • British Sanatorium of Rosario
    Rosario, S2000, Argentina
    Recruiting
  • Shanghai Institute of Hypertension
    Shanghai, Huangpu, China
    Recruiting
  • Jiangsu Province Official Hospital
    Jiangse, 210024, China
    Active, not recruiting

    Not enrolling at this site.

  • Ruijin Hospital North
    Shanghai, 200025, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2025, 55 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 55 months is above that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Jul 2, 2017
StartActual
May 11, 2021
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03206814
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
May 11, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 27, 2025

Study contacts

Gianfranco Parati, MD
Contact
gianfranco.parati@unimib.it
+390261911 ext. 2890
Paulina Wijnmaalen, MD
Contact
charge-app@auxologico.it
+390261911 ext. 2968
Gianfranco Parati, MD
principal investigator · Istituto Auxologico Italiano

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion